ArticleJournal of hematology & oncology2012
Effect of autoimmune diseases on incidence and survival in subsequent multiple myeloma.
Article in Journal of hematology & oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 6 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Risk of Hematologic Malignancies in Elderly Patients With Ankylosing Spondylitis: A Cohort Study and Systematic Review.Mayo Clinic proceedings · 2023Pooled it
- Comorbidities in polymyalgia rheumatica: a systematic review.Arthritis research & therapy · 2018Pooled it
- Risk of malignancy in ankylosing spondylitis: a systematic review and meta-analysis.Scientific reports · 2016Pooled it
- A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview.Multiple sclerosis (Houndmills, Basingstoke, England) · 2015Pooled it
- A systematic review of the incidence and prevalence of cancer in multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2015Pooled it
- Risk of multiple myeloma in rheumatoid arthritis: a meta-analysis of case-control and cohort studies.PloS one · 2014Pooled it
- Genetic architecture of multiple myeloma: From somatic alterations to germline susceptibility and clinical implications.Translational oncology · 2026Review
- Celiac Disease Emerging After ASCT in Multiple Myeloma: A Rare Diagnostic Intersection and Literature Review.Case reports in hematology · 2026Article
- Haematological malignancies in systemic sclerosis: a population-based nationwide register study.RMD open · 2025Article
- Monoclonal gammopathy is present in one fourth of patients undergoing renal biopsy but is pathogenic only in half of them.Journal of nephrology · 2025Observational
- Anti-GluK2 antibody-positive autoimmune encephalitis concurrent with multiple myeloma: a case report.BMC neurology · 2025Article
- Positive Anti-nuclear Antibody in Patients with Polyclonal Hypergammaglobulinemia Suggests the Presence of Multiple Distinct Comorbidities.Internal medicine (Tokyo, Japan) · 2024Article
- Increased Risk of Non-Hodgkin Lymphoma in Autoimmune Hepatitis: A Large Retrospective Cohort Study.Journal of clinical medicine · 2024Article
- Autoimmune Diseases and Plasma Cells Dyscrasias: Pathogenetic, Molecular and Prognostic Correlations.Diagnostics (Basel, Switzerland) · 2024Review
- The casual relationship between autoimmune diseases and multiple myeloma: a Mendelian randomization study.Clinical and experimental medicine · 2024Article
- Quantitative risk factor analysis of prior disease condition and socioeconomic status with the multiple myeloma development: nationwide cohort study.Scientific reports · 2024Article
- Cancer and Autoimmune Diseases: A Tale of Two Immunological Opposites?Frontiers in immunology · 2022Article
- VEXAS syndrome in myelodysplastic syndrome with autoimmune disorder.Experimental hematology & oncology · 2021Article
- Prognosis of young patients with monoclonal gammopathy of undetermined significance (MGUS).Blood cancer journal · 2021Article
- Second malignancies in multiple myeloma; emerging patterns and future directions.Best practice & research. Clinical haematology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with many types of autoimmune diseases (AIDs) are at an increased risk of cancer, which may depend on underlying dysregulation of the immune system or treatment. We systematically analyzed myeloma risk and survival in patients diagnosed with 33 different AIDs.
methodsData on patients with AIDs were retrieved from the Swedish Hospital Discharge Register and were linked to myeloma diagnoses from the Cancer Registry. Standardized incidence ratios (SIR) and hazard ratios (HRs) were calculated for subsequent myeloma between 1964 and 2008.
resultsAmong patients with the 33 AIDs analyzed, 457 cases of myeloma were diagnosed. The overall SIR for myeloma was 1.12 and the overall HR was 0.92 and non-significant. SIRs for myeloma were significantly increased after ankylosing spondylitis (2.02) and systemic sclerosis (2.63). Only the HR for myeloma after rheumatic fever (5.27) was significantly increased. The SIR for myeloma before age 60 years was 1.45; the SIR for myeloma was only increased in the period 1964-1990 (1.31) and not later (1.04). Only the SIR for myeloma after ankylosing spondylitis was increased in the period 1991-2008 (2.09); the HRs for myeloma were increased after polymyositis/dermatomyositis (6.44) and rheumatic fever (4.43) but there were only three deaths of myeloma after these AIDs.
conclusionsThe present data showed an increase in myeloma SIR after two AIDs, ankylosing spondylitis and systemic sclerosis, and in HR after rheumatic fever. The overall myeloma risk after any AID was no longer increased in the latter follow-up period of 1991 through 2008.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.